Unique ID issued by UMIN | UMIN000012584 |
---|---|
Receipt number | R000014721 |
Scientific Title | Effects of pravastatin and ezetimibe on inflammatory markers and endothelial function in dyslipidemic patients |
Date of disclosure of the study information | 2013/12/16 |
Last modified on | 2020/05/18 14:09:05 |
Effects of pravastatin and ezetimibe on inflammatory markers and endothelial function in dyslipidemic patients
Effects of pravastatin and ezetimibe on inflammatory markers and endothelial function
Effects of pravastatin and ezetimibe on inflammatory markers and endothelial function in dyslipidemic patients
Effects of pravastatin and ezetimibe on inflammatory markers and endothelial function
Japan |
dyslipidemia
Cardiology | Endocrinology and Metabolism | Adult |
Others
NO
This study is performed to investigate the effects of pravastatin and ezetimibe on inflammatory markers and endothelial function
Efficacy
(1) inflammatory molecules (CRP, TNFa, MCP-1, S100 proteins) in blood and white blood cells
(2) Flow-mediated vasodilation in brachial artery
(1) serum lipids
(2) diabetic parameters
(3) markers of obesity
(4) markers of oxidative stress
(5) maekers of chronic kidney diseases/renal injury
(6) urate in serum/urine
(7) adiposity
(8) blood pressures and pulse raate
Interventional
Cross-over
Randomized
Open -no one is blinded
Active
2
Treatment
Medicine |
Administration of pravastatin
Administration of ezetimibe
20 | years-old | <= |
80 | years-old | > |
Male and Female
1) Dyslipidemic patients whose LDL-C levels did not reach those recommended by Japan Atherosclerosis Society Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases
2) Outpatients
3) Subjects who gave written informed consent
1) Allergy against pravastatin or ezetimibe
2) Poor-controlled diabetes (HbA1c>10.0 %)
3) History of stroke, acute coronary syndrome or any cardiovascular diseases needed for inpatient-treatments within 6 months
4) Either level of aspartate aminotransaminase or alanine aminotransferase exceeds three-fold of the normal limits.
5) End stage renal disease
6) Symptomatic (NYHA III or IV) congestive heart failure
7) Malignancies or other diseases with poor prognosis
8) Pregnant
9) Subjects whose doctor in charge do not agree to join the trial
33
1st name | |
Middle name | |
Last name | Katsunori Ikewaki |
National Defense Medical College
Department of Internal Medicine
3-2 Namiki, Tokorozawa, JAPAN 359-8513
04-2995-1617
katsunorike@ndmc.ac.jp
1st name | |
Middle name | |
Last name | Makoto Ayaori |
National Defense Medical College
Department of Internal Medicine
3-2 Namiki, Tokorozawa, JAPAN 359-8513
04-2995-1617
ayaori@ndmc.ac.jp
National Defense Medical College
Foundation for Promotion of Defense Medicine
Non profit foundation
NO
2013 | Year | 12 | Month | 16 | Day |
Unpublished
No longer recruiting
2013 | Year | 11 | Month | 11 | Day |
2013 | Year | 11 | Month | 11 | Day |
2013 | Year | 12 | Month | 16 | Day |
2021 | Year | 03 | Month | 31 | Day |
2013 | Year | 12 | Month | 16 | Day |
2020 | Year | 05 | Month | 18 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000014721
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |